Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
By SquaredTown on October 1, 2025
BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today announced a settlement and license agreement with Amgen Inc. that clears the path...